Measuring Intralesional Drug Exposures in Cavitary TB using Noninvasive In Vivo PET Imaging

使用无创体内 PET 成像测量空洞结核病灶内药物暴露

• 批准号: 10027681
• 负责人: Sanjay Jain
• 金额: $ 81.62万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10027681
• 关键词: Aftercare; Anatomy; Animal Model; Animals; Antibiotic Resistance; Antibiotic Therapy; Antibiotics; Area; Autopsy; Autoradiography; Binding Proteins; Biodistribution; Cause of Death; Characteristics; Chemicals; Clinical; Data; Diagnostic radiologic examination; Disease; Dose; Drug Exposure; Drug Kinetics; Early identification; Emission-Computed Tomography; Evolution; Extinction (Psychology); Fiber; Goals; Health; Heterogeneity; Human; Image; Imaging Device; Immune; In Situ; Infection; Inflammation; Kinetics; Lesion; Linezolid; Link; Lung; Mass Spectrum Analysis; Measurement; Measures; Modeling; Multidrug-Resistant Tuberculosis; Multimodal Imaging; Mus; Mycobacterium tuberculosis; National Institute of Allergy and Infectious Disease; Oryctolagus cuniculus; Outcome; Parents; Pathologic; Patients; Penetration; Pharmaceutical Preparations; Phenotype; Plasma; Population; Positron-Emission Tomography; Property; Recommendation; Recurrence; Regimen; Relapse; Research; Resistance; Rifampin; Risk Factors; Sampling Biases; Site; Strategic Planning; System; Time; Tissue Sample; Tissues; Tracer; Translating; Treatment Factor; Treatment Failure; Treatment outcome; Tuberculosis; World Health Organization; X-Ray Computed Tomography; analog; antimicrobial; bactericide; base; bioimaging; clinically translatable; cohort; density; design; drug development; early detection biomarkers; effective therapy; emerging antibiotic resistance; experimental study; first-in-human; human disease; imaging biomarker; in vivo; in vivo imaging; insight; macrophage; molecular imaging; novel; novel therapeutics; pathogen; pharmacokinetic model; tool; treatment optimization; treatment risk; treatment strategy; tuberculosis drugs; tuberculosis treatment

Effective treatment of infections depends on achieving adequate antibiotic concentrations at infection sites, where the pathogen resides. However, with few exceptions, current antibiotic dosing recommendations are based on achievable plasma concentrations, without specific information on drug concentrations at the site of infection. However, plasma drug levels do not correlate well with those at infection sites. Cavitary lesions, which are the hallmark of human tuberculosis (TB), have limited drug penetration and consequently are a risk factor for treatment failure, recurrence, and the emergence of antibiotic resistance. Direct tissue measurements are invasive, can be performed in humans only when clinically indicated, and generally provide data at a single time-point even in animal models. Additionally, given that multiple, pathologically distinct TB lesions coexist within the same infected-host simultaneously, measurements from one or a few easily accessible lesions are subject to sampling bias. Finally, current antibiotic treatment strategies are designed for efficacy (e.g. >85%) at a population level, but ignore the inter- and intra-subject heterogeneity. While shorter treatments could cure e.g. >70%, tools to identify patients at-risk for treatment failure or requiring longer treatments are needed. We have developed novel tools to perform noninvasive, simultaneous and unbiased, multi-compartment in situ measurements of antibiotic concentration-time profiles. First-in-human, whole-body dynamic 11C-rifampin positron emission tomography (PET) and computed tomography (CT) were performed in newly identified patients with rifampin-susceptible TB. PET demonstrated spatially compartmentalized rifampin exposures in the multiple, pathologically distinct TB lesions in the same patient, with low cavitary tissue rifampin exposures. Repeat PET/CT measurements demonstrated independent temporal evolution of rifampin exposure trajectories in different lesions within the same patient. Similar findings were re-capitulated by PET/CT in experimentally infected rabbits with cavitary TB and confirmed using post-mortem analyses. Integrated modeling of the PET- captured concentration-time profiles in hollow-fiber bacterial kill-curve experiments identified that 35 mg/kg/day of rifampin is needed to achieve cure in four months for cavitary disease. Optimized antibiotic dosing could shorten current treatments. Conversely, suboptimal dosing is a major factor for treatment failure and antibiotic resistance, which the World Health Organization declared as one of the top ten threats to human health. Our overall goals are to leverage our expertise in novel in vivo imaging tools, animal models of cavitary TB and hollow-fiber systems to gain mechanistic insights about TB treatments: a) measure the spatial and temporal distribution of TB drugs active against multi-drug resistant TB (bedaquiline, pretonamid, linezolid regimen) and optimize cavitary TB treatments; b) identify the key factors contributing to treatment failure, long- term (relapse-free) cure or able to guide treatments and; c) develop imaging (pathogen-specific or radiography- based) biomarkers for early identification of subjects at-risk for treatment failure or requiring longer treatments.

感染的有效治疗取决于在感染部位达到足够的抗生素浓度，